Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches

References

• AbruzzeseECantonettiMMorinoL2003CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reportsJ Clin Oncol214256814615464
   PubMed Web of Science ®Google Scholar
• AbdelhalimABarcosMBlockAW2007Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapyLeuk Lymphoma481053617487757
   PubMed Web of Science ®Google Scholar
• AgisHMannhalterCSperrWR2004Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantationLeuk Lymphoma451453815359647
   PubMed Web of Science ®Google Scholar
• AngstreichGRMatsuiWHuffCA2005Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitorsBr J Haematol1303738116042686
   PubMed Web of Science ®Google Scholar
• AichbergerKJHerndlhoferSAgisH2007Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukemia occurring during imatinib therapyEur J Clin Invest378081317727673
   PubMed Web of Science ®Google Scholar
• AzamMLatekRRDaleyGQ2003Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABLCell1128314312654249
   PubMed Web of Science ®Google Scholar
• BaccaraniMSaglioGGoldmanJ2006Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood10818092016709930
   PubMed Web of Science ®Google Scholar
• BarbanyGHoglundMSimonssonBSwedish CML Group2002Complete molecular remission in chronic myelogenous leukemia after imatinib therapyN Engl J Med3475394012181416
   PubMed Web of Science ®Google Scholar
• BarnesDJMeloJV2006Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemiaCell Cycle52862617172863
   PubMed Web of Science ®Google Scholar
• BartheCGharbiMJLagardeV2002Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571Br J Haematol1191091112358910
   PubMed Web of Science ®Google Scholar
• BhatiaRHoltzMNiuNPersistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatmentBlood1014701712576334
   PubMed Web of Science ®Google Scholar
• BiernauxCLoosMSelsAHuezGStryckmansP1995Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individualsBlood863118227579406
   PubMed Web of Science ®Google Scholar
• BoltonAEPengBHubertM2004Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjectsCancer Chemother Pharmacol53102614605865
   PubMed Web of Science ®Google Scholar
• BornhäuserMJenkeAFreiberg-RichterJ2004CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluidAnn Hematol83401214673623
   PubMed Web of Science ®Google Scholar
• BoseSDeiningerMGora-TyborJ1998The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual diseaseBlood92336279787174
   PubMed Web of Science ®Google Scholar
• BranfordSRudzkiZWalshS2002High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBlood993472511964322
   PubMed Web of Science ®Google Scholar
• BranfordSRudzkiZWalshS2003Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood1022768312623848
   PubMed Web of Science ®Google Scholar
• BreedveldPBeijnenJHSchellensJH2006Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugsTrends Pharmacol Sci27172416337012
   PubMed Web of Science ®Google Scholar
• BreedveldPPluimDCiprianiG2005The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patientsCancer Res6525778215805252
   PubMed Web of Science ®Google Scholar
• BrecciaMDiverioDPaneF2006Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferonLeuk Res301577916630657
   PubMed Web of Science ®Google Scholar
• BrendelCScharenbergCDohseM2007Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cellsLeukemia 20072112677517519960
   PubMed Web of Science ®Google Scholar
• BurgerHNooterK2004Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinibCell Cycle31502515611623
   PubMed Web of Science ®Google Scholar
• BurgerHvan TolHBrokM2005Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumpsCancer Biol Ther47475215970668
   PubMed Web of Science ®Google Scholar
• CalabrettaBPerrottiD2004The biology of CML blast crisisBlood10340102214982876
   PubMed Web of Science ®Google Scholar
• CampbellLJPatsourisCRayerouxKC2002BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administrationCancer Genet Cytogenet13930312547154
   PubMed Web of Science ®Google Scholar
• CarterTAWodickaLMShahNP2005Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesProc Natl Acad Sci USA10211011616046538
   PubMed Web of Science ®Google Scholar
• CheethamGMCharltonPAGolecJM2007Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680Cancer Lett251323917240048
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGJohnsonJR2002Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemiaClin Cancer Res89354212006504
   PubMed Web of Science ®Google Scholar
• CoplandMHamiltonAElrickLJ2006Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fractionBlood1074532916469872
   PubMed Web of Science ®Google Scholar
• CoplandMJorgensenHGHolyoakeTL2005Evolving molecular therapy for chronic myeloid leukaemia – are we on targetHematology103495916203604
   PubMed Web of Science ®Google Scholar
• CortesJKantarjianH2003Advanced-phase chronic myeloid leukemiaSemin Hematol40798612563614
   PubMed Web of Science ®Google Scholar
• CortesJETalpazMGilesF2003Prognostic significance of cytoge-netic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyBlood101379480012560227
   PubMed Web of Science ®Google Scholar
• CortesJRousselotPKimDW2007Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood10932071317185463
   PubMed Web of Science ®Google Scholar
• CortesJETalpazMO’BrienS2006Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposalCancer10613061516463391
   PubMed Web of Science ®Google Scholar
• Cowan-JacobSWGuezVFendrichG2004Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatmentMini Rev Med Chem42859915032675
   PubMed Web of Science ®Google Scholar
• DaleyGQVan EttenRABaltimoreD1990Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosomeScience247824302406902
   PubMed Web of Science ®Google Scholar
• de KleinAvan KesselAGGrosveldG1982A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemiaNature30076576960256
   PubMed Web of Science ®Google Scholar
• DaiHMarbachPLemaireM2003Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated effluxJ Pharmacol Exp Ther30410859212604685
   PubMed Web of Science ®Google Scholar
• DeiningerMW2007Optimizing therapy of chronic myeloid leukemiaExp Hematol35S11445417379100
   PubMed Web of Science ®Google Scholar
• DevireddyLRGazinCZhuXGreenMR2005A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptakeCell123129330516377569
   PubMed Web of Science ®Google Scholar
• Diaz-BlancoEBrunsINeumannF2007Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phaseLeukemia2149450417252012
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSG2006Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med35524081717151364
   PubMed Web of Science ®Google Scholar
• DrukerBJSawyersCLKantarjianH2001Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosomeN Engl J Med34410384211287973
   PubMed Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJ2001Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med3441031711287972
   PubMed Web of Science ®Google Scholar
• DutcherJPWiernikPH2000Accelerated and blastic phase of chronic myeloid leukemiaCurr Treat Options Oncol1516212057061
   PubMedGoogle Scholar
• DutreixCPengBMehringG2004Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjectsCancer Chemother Pharmacol54290415138710
   PubMed Web of Science ®Google Scholar
• EavesACBarnettMJPonchioLCashmanJDPetzerALEavesCJ1998Differences between normal and CML stem cells: potential targets for clinical exploitationStem Cells16S1778311012149
   PubMedGoogle Scholar
• EavesCUdomsakdiCCashmanJ1993The biology of normal and neoplastic stem cells in CMLLeuk Lymphoma11S1245538251904
   PubMed Web of Science ®Google Scholar
• EckelFvon DeliusSMayrM2005Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinomaOncology693637116319507
   PubMed Web of Science ®Google Scholar
• EistererWJiangXChristO2005Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human diseaseLeukemia194354115674418
   PubMed Web of Science ®Google Scholar
• ElrickLJJorgensenHGMountfordJCHolyoakeTL2005Punish the parent not the progenyBlood1051862615528314
   PubMed Web of Science ®Google Scholar
• FryeRFFitzgeraldSMLagattutaTF2004Effect of St John’s wort on imatinib mesylate pharmacokineticsClin Pharmacol Ther76323915470331
   PubMed Web of Science ®Google Scholar
• GadzickiDvon NeuhoffNSteinemannD2005BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinibCancer Genet Cytogenet159164715899391
   PubMed Web of Science ®Google Scholar
• GargalloPMCuelloMTArangurenPN2003Amplification of the BCR/ABL fusion gene clustered on a masked Philadelphia chromosome in a patient with myeloblastic crisis of chronic myelocytic leukemiaCancer Genet Cytogenet143140412781448
   PubMed Web of Science ®Google Scholar
• GilesFJCortesJEKantarjianHMO’BrienSM2004Accelerated and blastic phases of chronic myelogenous leukemiaHematol Oncol Clin North Am187537415271404
   PubMed Web of Science ®Google Scholar
• GilesFJCortesJJonesD2007MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutationBlood109500216990603
   PubMed Web of Science ®Google Scholar
• GiraltSAAroraMGoldmanJM2007Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemiaBr J Haematol137461717459051
   PubMed Web of Science ®Google Scholar
• GishizkyMLWitteON1992Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitroScience25683691375394
   PubMed Web of Science ®Google Scholar
• GoldmanJGordonM2006Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matterLeuk Lymphoma471716321820
   PubMed Web of Science ®Google Scholar
• GoldmanJMApperleyJFJonesL1986Bone marrow transplantation for patients with chronic myeloid leukemiaN Engl J Med31420273510388
   PubMed Web of Science ®Google Scholar
• GorreMEMohammedMEllwoodK2001Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplificationScience2938768011423618
   PubMed Web of Science ®Google Scholar
• GrahamSMJorgensenHGAllanE2002Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitroBlood993192511756187
   PubMed Web of Science ®Google Scholar
• GratwohlAHermansJGoldmanJM1998Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLancet3521087929798583
   PubMed Web of Science ®Google Scholar
• GriswoldIJMacPartlinMBummT2006Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinibMol Cell Biol2660829316880519
   PubMed Web of Science ®Google Scholar
• GschwindHPPfaarUWaldmeierFPokornyRSeiberlingMBen-AmMPengBGrossG2005Metabolism and disposition of imatinib mesylate in healthy volunteersDrug Metab Dispos3315031216006570
   PubMed Web of Science ®Google Scholar
• GuilhotFApperleyJKimDW2007Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood10941435017264298
   PubMed Web of Science ®Google Scholar
• GumireddyKBakerSJCosenzaSC2005A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistanceProc Natl Acad Sci USA1021992715677719
   PubMed Web of Science ®Google Scholar
• HerweijerHSonneveldPBaasFNooterK1990Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporineJ Natl Cancer Inst821133401972761
   PubMed Web of Science ®Google Scholar
• HochhausAErbenPErnstTMuellerMC2007Resistance to targeted therapy in chronic myelogenous leukemiaSemin Hematol44S152417292737
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHMBaccaraniM2007Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood1092303917138817
   PubMed Web of Science ®Google Scholar
• HochhausAKreilSCorbinAS2002Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyLeukemia162190612399961
   PubMed Web of Science ®Google Scholar
• HolyoakeTLHorrocksCThomasT2000Cell separation improves the sensitivity of detecting rare human normal and leukemic hematopoietic cells in vivo in NOD/SCID miceCytotherapy24112112044221
   PubMed Web of Science ®Google Scholar
• HolyoakeTLJiangXDrummondMW2002Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemiaLeukemia165495811960331
   PubMed Web of Science ®Google Scholar
• HolyoakeTLJiangXJorgensenHG2001Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3Blood97720811157490
   PubMed Web of Science ®Google Scholar
• HooverRRGerlachMJKohEYDaleyGQ2001Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cellsOncogene2058263511593388
   PubMed Web of Science ®Google Scholar
• HughesTPKaedaJBranfordS2003Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaN Engl J Med34914233214534335
   PubMed Web of Science ®Google Scholar
• IllmerTSchaichMPlatzbeckerU2004P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylateLeukemia18401814724652
   PubMed Web of Science ®Google Scholar
• JabbourECortesJKantarjianHM2006Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failureBlood1081421316601247
   PubMed Web of Science ®Google Scholar
• JabbourECortesJKantarjianH2007Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicityCancer1103404417559140
   PubMed Web of Science ®Google Scholar
• JabbourECortesJO’BrienS2007New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistanceSemin Hematol44S1S253117292738
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHMAbruzzoL2007Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phaseBlood
   Web of Science ®Google Scholar
• JabbourEKantarjianHJonesD2006Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateLeukemia2017677316855631
   PubMed Web of Science ®Google Scholar
• JiangXSawKMEavesAEavesC2007Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cellsJ Natl Cancer Inst996809317470736
   PubMed Web of Science ®Google Scholar
• JiangXZhaoYSmithC2007Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapiesLeukemia219263517330101
   PubMed Web of Science ®Google Scholar
• KantarjianHMCortesJO’BrienS2002Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseBlood9935475311986206
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFWunderleL2006Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLN Engl J Med35425425116775235
   PubMed Web of Science ®Google Scholar
• KantarjianHSawyersCHochhausA2002Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaN Engl J Med3466455211870241
   PubMed Web of Science ®Google Scholar
• KantarjianHMTalpazMGilesF2006New insights into the patho-physiology of chronic myeloid leukemia and imatinib resistanceAnn Intern Med1459132317179059
   PubMed Web of Science ®Google Scholar
• KantarjianHMTalpazMO’BrienS2003Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaBlood101473512393385
   PubMed Web of Science ®Google Scholar
• KhorashadJSAnandMMarinD2006The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinibLeukemia206586316467863
   PubMed Web of Science ®Google Scholar
• KimHJJungCWKimK2006Isolated blast crisis in CNS in a patient with chronic myelogenous leukaemia maintaining major cytogenetic response after imatinibJ Clin Oncol2440282916921058
   PubMed Web of Science ®Google Scholar
• KimuraSNaitoHSegawaH2005NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemiaBlood10639485416105974
   PubMed Web of Science ®Google Scholar
• KreuzerKALe CoutrePLandtO2003Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping techniqueAnn Hematol82284912692682
   PubMed Web of Science ®Google Scholar
• le CoutrePKreuzerKAPurscheS2004Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588Cancer Chemother Pharmacol533132314658008
   PubMed Web of Science ®Google Scholar
• le CoutrePTassiEVarella-GarciaM2000Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplificationBlood9517586610688835
   PubMed Web of Science ®Google Scholar
• LeisJFStepanDECurtinPT2004Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571)Leuk Lymphoma45695815160941
   PubMed Web of Science ®Google Scholar
• LiZQiaoYLiuB2005Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemiaClin Cancer Res114460815958631
   PubMed Web of Science ®Google Scholar
• LinHMonacoGSunT2005Bcr-Abl-mediated suppression of normal hematopoiesis in leukemiaOncogene2432465615735695
   PubMed Web of Science ®Google Scholar
• LinYBruyereHHorsmanDE2006Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factorsCancer Genet Cytogenet170162316965950
   PubMed Web of Science ®Google Scholar
• LoriauxMDeiningerM2004Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinibLeuk Lymphoma45219720315512807
   PubMed Web of Science ®Google Scholar
• LugoTGPendergastAMMullerAJWitteON1990Tyrosine kinase activity and transformation potency of bcr-abl oncogene productsScience2471079822408149
   PubMed Web of Science ®Google Scholar
• MahonFXBellocFLagardeV2003MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsBlood10123687312609962
   PubMed Web of Science ®Google Scholar
• MarktelSMarinDFootN2003Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progressionHaematologica88260712651263
   PubMed Web of Science ®Google Scholar
• MartinelliGSoveriniSRostiG2005New tyrosine kinase inhibitors in chronic myeloid leukemiaHaematologica905344115820950
   PubMed Web of Science ®Google Scholar
• MatsudaMMoritaYShimadaT2005Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylateInt J Hematol81307915914360
   PubMed Web of Science ®Google Scholar
• MedinaJKantarjianHTalpazM2003Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phaseCancer9819051114584073
   PubMed Web of Science ®Google Scholar
• MeloJVBarnesDJ2007Chronic myeloid leukaemia as a model of disease evolution in human cancerNat Rev Cancer74415317522713
   PubMed Web of Science ®Google Scholar
• MeloJVDeiningerMW2004Biology of chronic myelogenous leukemia – signaling pathways of initiation and transformationHematol Oncol Clin North Am185456815271392
   PubMed Web of Science ®Google Scholar
• MenzelHvon BubnoffNHochhausA2007Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinibBone Marrow Transplant4083417450179
   PubMed Web of Science ®Google Scholar
• MichorFHughesTPIwasaY2005Dynamics of chronic myeloid leukaemiaNature43512677015988530
   PubMed Web of Science ®Google Scholar
• MorelFBrisMJHerryA2003Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinibEur J Haematol70235912656747
   PubMed Web of Science ®Google Scholar
• NavarroJTFeliuEGrauJ2007Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcomeAm J Hematol828495117563075
   PubMed Web of Science ®Google Scholar
• NevianiPSanthanamRTrottaR2006The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET proteinCancer Cell535568
   Google Scholar
• Nguyen KhacFWaillMCRomanaSP2002Identical abnormality of the short arm of chromosome 18 in two Philadelphia-positive chronic myelocytic leukemia patients with erythroblastic transformation, resulting in duplication of BCR-ABL1 fusionCancer Genet Cytogenet13822612419580
   PubMedGoogle Scholar
• NicoliniFECormSLeQH2006Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)Leukemia201061616642048
   PubMed Web of Science ®Google Scholar
• NowellPCHungerfordDA1960A minute chromosome in human granulocytic leukemiaScience1321497
   Web of Science ®Google Scholar
• O’BrienSGGuilhotFLarsonRA2003Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med348994100412637609
   PubMed Web of Science ®Google Scholar
• O’BrienSGMeinhardtPBondE2003Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemiaBr J Cancer891855914612892
   PubMed Web of Science ®Google Scholar
• O’DwyerMEMauroMJBlasdelC2004Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylateBlood103451514512312
   PubMed Web of Science ®Google Scholar
• O’HareTWaltersDKStoffregenEPJiaTManleyPWMestanJCowan-JacobSWLeeFYHeinrichMCDeiningerMWDrukerBJ2005In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsCancer Res654500515930265
   PubMed Web of Science ®Google Scholar
• PappasPKaravasilisVBriasoulisE2005Pharmacokinetics of imatinib mesylate in end stage renal disease. A case studyCancer Chemother Pharmacol563586015883819
   PubMed Web of Science ®Google Scholar
• PavluJCzepulkowskiBKaczmarskiRJan-MohamedR2005Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinibLancet Oncol612815683824
   PubMed Web of Science ®Google Scholar
• PendergastAMQuilliamLACripeLD1993BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor proteinCell75175858402896
   PubMed Web of Science ®Google Scholar
• PengBDutreixCMehringG2004Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusionJ Clin Pharmacol441586214747424
   PubMed Web of Science ®Google Scholar
• PengBHayesMRestaD2004Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patientsJ Clin Oncol229354214990650
   PubMed Web of Science ®Google Scholar
• PengCBrainJHuY2007Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cellsBlood1106788517395781
   PubMed Web of Science ®Google Scholar
• PengBLloydPSchranH2005Clinical pharmacokinetics of imatinibClin Pharmacokinet448799416122278
   PubMed Web of Science ®Google Scholar
• PicardSTitierKEtienneG2007Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood1093496917192396
   PubMed Web of Science ®Google Scholar
• Pienkowska-GrelaBWoronieckaRSolarskaI2007Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcriptCancer Genet Cytogenet174111517452251
   PubMed Web of Science ®Google Scholar
• PuilLLiuJGishG1994Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathwayEMBO J13764738112292
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHJonesD2007Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureBlood109497916990591
   PubMed Web of Science ®Google Scholar
• RadichJPDaiHMaoM2006Gene expression changes associated with progression and response in chronic myeloid leukemiaProc Natl Acad Sci USA1032794916477019
   PubMed Web of Science ®Google Scholar
• RahmaniMNguyenTKDentP2007The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant BCR/ABL+ human leukemia cells in association with STAT5 inhibition and MCL-1 downregulationMol Pharmacol727889517595328
   PubMed Web of Science ®Google Scholar
• RajappaSUppinSGRaghunadharaoD2004Isolated central nervous system blast crisis in chronic myeloid leukaemiaHematol Oncol221798115995975
   PubMed Web of Science ®Google Scholar
• RenR2005Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemiaNat Rev Cancer51728315719031
   PubMed Web of Science ®Google Scholar
• Roche-LestienneCPreudhommeC2003Mutations in the ABL kinase domain pre-exist the onset of imatinib treatmentSemin Hematol40S280212783380
   PubMed Web of Science ®Google Scholar
• Roche-LestienneCSoenen-CornuVGrardel-DuflosN2002Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood1001014812130516
   PubMed Web of Science ®Google Scholar
• RoederIHornMGlaucheIHochhausAMuellerMCLoefflerM2006Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implicationsNat Med121181417013383
   PubMed Web of Science ®Google Scholar
• RoumiantsevSShahNPGorreME2002Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loopProc Natl Acad Sci USA9910700512149456
   PubMed Web of Science ®Google Scholar
• RousselotPHuguetFReaD2007Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood109586016973963
   PubMed Web of Science ®Google Scholar
• RowleyJD1973A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa stainingNature24329034126434
   PubMed Web of Science ®Google Scholar
• RyttingMEWierdaWG2004Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapyLeuk Lymphoma451623615370215
   PubMed Web of Science ®Google Scholar
• SattlerMGriffinJD2003Molecular mechanisms of transformation by the BCR-ABL oncogeneSemin Hematol4041012783368
   PubMed Web of Science ®Google Scholar
• SawyersCLHochhausAFeldmanE2002Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood993530911986204
   PubMed Web of Science ®Google Scholar
• SeniorK2003Gleevec does not cross blood-brain barrierLancet Oncol419812681250
   PubMed Web of Science ®Google Scholar
• ShahNPNicollJMNagarB2002Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell21172512204532
   PubMed Web of Science ®Google Scholar
• ShahNPTranCLeeFY2004Overriding imatinib resistance with a novel ABL kinase inhibitorScience30539940115256671
   PubMed Web of Science ®Google Scholar
• ShetASJahagirdarBNVerfaillieCM2002Chronic myelogenous leukemia: mechanisms underlying disease progressionLeukemia1614021112145676
   PubMed Web of Science ®Google Scholar
• SilbermanGCrosseMGPetersonEA1994Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countriesN Engl J Med331106378090167
   PubMed Web of Science ®Google Scholar
• SillaberCGesbertFFrankDA2000STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cellsBlood9521182510706883
   PubMed Web of Science ®Google Scholar
• SkaggsBJGorreMERyvkinA2006Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutantsProc Natl Acad Sci USA103194667117164333
   PubMed Web of Science ®Google Scholar
• SkorskiTBellacosaANieborowska-SkorskaM1997Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathwayEMBO J166151619321394
   PubMed Web of Science ®Google Scholar
• SoveriniSMartinelliGRostiG2005ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid LeukemiaJ Clin Oncol234100915867198
   PubMed Web of Science ®Google Scholar
• TakayamaNSatoNO’BrienSG2002Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluidBr J Haematol119106812358909
   PubMed Web of Science ®Google Scholar
• TalpazMShahNPKantarjianH2006Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasN Engl J Med35425314116775234
   PubMed Web of Science ®Google Scholar
• TalpazMSilverRTDrukerBJ2002Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood9919283711877262
   PubMed Web of Science ®Google Scholar
• TanakaKArifMKyoT2000Transposition of duplicated chromosomal segment involving fused BCR-ABL gene or ABL oncogene alone in chronic myelocytic leukemia and Ph chromosome-positive acute leukemia with complex karyotypesCancer Genet Cytogenet11981410812164
   PubMedGoogle Scholar
• TauchiTOhyashikiK2006The second generation of BCR-ABL tyrosine kinase inhibitorsInt J Hematol8329430016757427
   PubMed Web of Science ®Google Scholar
• TerreCEclacheVRousselotP2004Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemiaLeukemia181340615190256
   PubMed Web of Science ®Google Scholar
• ThomasJWangLClarkREPirmohamedM2004Active transport of imatinib into and out of cells: implications for drug resistanceBlood10437394515315971
   PubMed Web of Science ®Google Scholar
• TsengPHLinHPZhuJ2005Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistanceBlood1054021715665113
   PubMed Web of Science ®Google Scholar
• Van EttenRA2007Oncogenic signaling: new insights and controversies from chronic myeloid leukemiaJ Exp Med204461517353369
   PubMed Web of Science ®Google Scholar
• VerbeekWKonigHBoehmJ2006Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemiaActa Haematol1151091216424660
   PubMed Web of Science ®Google Scholar
• VilluendasRSteegmannJLPollanM2006Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approachLeukemia2010475416598311
   PubMed Web of Science ®Google Scholar
• VolpeGCignettiAPanuzzoC2007Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approachesCancer Res675300717545610
   PubMed Web of Science ®Google Scholar
• von BubnoffNSchnellerFPeschelC2002BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective studyLancet3594879111853795
   PubMed Web of Science ®Google Scholar
• WangLGiannoudisALaneS2007Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemiaClin Pharmacol Ther10.1038/sj.clpt.6100268
   Web of Science ®Google Scholar
• WeisbergEManleyPWBreitensteinW2005Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell71294115710326
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPMestanJ2006AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLBr J Cancer941765916721371
   PubMed Web of Science ®Google Scholar
• WeisbergECatleyLWrightRD2007Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemiasBlood10921122017068153
   PubMed Web of Science ®Google Scholar
• WeisbergEGriffinJD2000Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell linesBlood95349850510828035
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPWCowan-JacobSW2007Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemiaNat Rev Cancer73455617457302
   PubMed Web of Science ®Google Scholar
• WeisserMSchleuningMHaferlachC2007Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapyLeuk Lymphoma4829530117325889
   PubMed Web of Science ®Google Scholar
• WestermannJKoppJvan LessenA2007Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemiaBr J Haematol13729730617408402
   PubMed Web of Science ®Google Scholar
• WetzlerMTalpazMVan EttenRA1993Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiationJ Clin Invest921925398408645
   PubMed Web of Science ®Google Scholar
• WhiteDLSaundersVAQuinnSR2007Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugsBlood10936091017409347
   PubMed Web of Science ®Google Scholar
• WildRCastanedaSFleflehC2004BMS-354825, a dual SRC/ABL kinase inhibitor, displays potent anti-tumor activity in a model of intracranial CML growthBlood104549a
   Web of Science ®Google Scholar
• WolffNCRichardsonJAEgorinMIlariaRL2003The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemiaBlood1015010312595307
   PubMed Web of Science ®Google Scholar
• YokotaAKimuraSMasudaS2007INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activityBlood1093061416954504
   PubMed Web of Science ®Google Scholar
• ZhengCLiLHaakM2006Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisisLeukemia2010283416617318
   PubMed Web of Science ®Google Scholar